KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to 0.19.

  • Bristol Myers Squibb's Equity Ratio rose 454.68% to 0.19 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.19, marking a year-over-year increase of 454.68%. This contributed to the annual value of 0.18 for FY2024, which is 4288.51% down from last year.
  • As of Q3 2025, Bristol Myers Squibb's Equity Ratio stood at 0.19, which was up 454.68% from 0.18 recorded in Q2 2025.
  • Bristol Myers Squibb's 5-year Equity Ratio high stood at 0.47 for Q4 2022, and its period low was 0.17 during Q1 2024.
  • In the last 5 years, Bristol Myers Squibb's Equity Ratio had a median value of 0.32 in 2023 and averaged 0.29.
  • As far as peak fluctuations go, Bristol Myers Squibb's Equity Ratio skyrocketed by 1495.06% in 2022, and later crashed by 5059.19% in 2024.
  • Bristol Myers Squibb's Equity Ratio (Quarter) stood at 0.41 in 2021, then grew by 14.95% to 0.47 in 2022, then tumbled by 33.58% to 0.31 in 2023, then crashed by 42.89% to 0.18 in 2024, then grew by 8.48% to 0.19 in 2025.
  • Its Equity Ratio stands at 0.19 for Q3 2025, versus 0.18 for Q2 2025 and 0.19 for Q1 2025.